Αποτελέσματα Αναζήτησης
GBM is the most malignant form of primary brain tumor with an extremely poor prognosis. Adult GBM patients with classical treatment have a 5-year survival rate of less than 10%. Our results suggest that patients diagnosed with GBM at an older age have a shorter survival period.
- PubMed
Glioblastoma multiforme (GBM) is a WHO grade IV glioma and...
- PMC Free Article
Glioblastoma (GBM) is the most common and aggressive primary...
- PubMed
15 Ιαν 2020 · Kaplan-Maier analysis revealed that older patients (≥ 45 years) displayed worse prognosis than those aged under 45 years (P = 0.038). Dismal prognosis was also associated with clinical parameters, including high tumor grade, multiple lesions, and Karnofsky performance score (KPS).
14 Αυγ 2024 · What is the prognosis (outlook) for people who have glioblastoma? Glioblastoma is an aggressive cancer that’s difficult to treat. There isn’t a reliable cure. Treatments ease symptoms. They help you stay comfortable and prolong your life. There are many clinical trials underway to find new GBM treatments.
15 Ιουλ 2020 · Translation of survival benefits observed in glioblastoma clinical trials to populations and to longer-term survival remains uncertain. We aimed to assess if ≥ 2-year survival has changed in...
Glioblastoma multiforme (GBM) is a WHO grade IV glioma and the most common malignant, primary brain tumor with a 5-year survival of 7.2%. Its highly infiltrative nature, genetic heterogeneity, and protection by the blood brain barrier (BBB) have posed great treatment challenges.
Although GBM is rare tumor with global incidence of less than 10 per 100,000 people, its poor prognosis with survival rate of 14-15 months after diagnosis makes it a crucial public health issue (Iacob & Dinca, 2009; Thakkar et al., 2014).
Glioblastoma (GBM) is the most common and aggressive primary CNS malignancy with a median survival of 15 months. The average incidence rate (IR) of GBM is 3.19/100,000 population and the median age of diagnosis is 64 years.
